Abstract
Venous thromboembolism (VTE) is an important complication in cancer patients, which is associated with bad outcome. Increased recurrence rates and bleeding complications as compared to non-cancer patients during the treatment of VTE, require special attention. This review aims to summarize the available evidence on both the anticoagulant and non-anticoagulant treatment of symptomatic VTE in patients with active malignancy.